News
The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. Descovy is not indicated in individuals at risk of HIV-1 infection from receptive vaginal sex because the effectivness in this population has not been evaluated.
ADM Brett Giroir, MD, Assistant Secretary for Health, recently spoke to the American Public Health Association (APHA) about Ending the HIV Epidemic:
Dr. Linda-Gail Bekker began a two-year term as president of the International AIDS Society.
Much has changed since the global HIV community convened at the previous International AIDS Conference in Durban in 2016.